Search results for "AGENT"

showing 10 items of 8904 documents

Dominant frequency and complexity of electrical reentrant activation during ventricular fibrillation with releasing of NO after acute local stretchin…

2013

medicine.medical_specialtybusiness.industryRabbit heartCardiac arrhythmiaDominant frequencymedicine.diseaseReentrancyInternal medicineVentricular fibrillationCardiologymedicineMyocyteCardiology and Cardiovascular MedicinebusinessPerfusionInotropic agentEuropean Heart Journal
researchProduct

Herpes zóster posvacunal: valor del citodiagnóstico de Tzank

2016

medicine.medical_specialtybusiness.industryTolonium chlorideDiagnostico diferencialColoring agentsDermatologyPediatricsRJ1-570030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistry030225 pediatricsPediatrics Perinatology and Child HealthmedicinebusinessChickenpox VaccineAnales de Pediatría
researchProduct

Absorption of drugs from the bladder and intravesical chemotherapy

1976

medicine.medical_specialtybusiness.industryUrologyUrinary BladderUrologyAntineoplastic AgentsPharmaceutical PreparationsUrinary Bladder NeoplasmsInjections IntravenousAnimalsHumansMedicineRabbitsIntravesical chemotherapybusinessAbsorption (electromagnetic radiation)ThiotepaUrological Research
researchProduct

Die Beeinflu�ung postmortaler physikalisch-chemischer Vorg�nge durch Antibiotica und Sulfonamide

1961

medicine.medical_specialtybusiness.industrymedicine.drug_classAntibioticsMEDLINESulfanilamideMedical lawDermatologyPathology and Forensic MedicinePhysical chemicalDermatologic agentsmedicinebusinessmedicine.drugDeutsche Zeitschrift f�r die Gesamte Gerichtliche Medizin
researchProduct

Management of Antiaggregated and Anticoagulated Patients Scheduled for Thoracic Surgery: Recommendations for Venous Thromboprophylaxis

2017

The management of patients under the effect of antiplatelet or anticoagulant agents is a common challenge in thoracic surgery. Their temporary interruption or continuation needs a balanced assessment between the risk of thrombosis (interruption) and bleeding (continuation). Moreover, most patients must receive an anticoagulant for thromboprophylaxis (mainly a low-molecular-weight heparin). So, it is important to have in mind all surgical and anaesthetic implications of these drugs to take the optimal decision in each case.

medicine.medical_specialtybusiness.industrymedicine.drug_classmedicine.medical_treatmentAnticoagulantPercutaneous coronary interventionHeparinmedicine.diseaseThrombosisMechanical heart-valveSurgeryCardiothoracic surgerymedicineStent implantationAnticoagulant AgentIntensive care medicinebusinessmedicine.drug
researchProduct

In-hospital outcomes of catheter-directed thrombolysis in patients with pulmonary embolism

2020

Abstract Background and purpose Catheter-directed treatment of acute pulmonary embolism (PE) is technically advancing. Recent guidelines acknowledge this treatment option for patients with overt or imminent haemodynamic decompensation, particularly when systemic thrombolysis is contraindicated or has failed. We investigated baseline characteristics and in-hospital outcomes of patients with PE who underwent catheter-directed thrombolysis (CDT) in the German nationwide inpatient cohort. Methods Data from hospitalizations with PE between 2005 and 2016 were collected by the Federal Office of Statistics (Statistisches Bundesamt) in Germany and included in this analysis. Patients with PE who unde…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentMortality rateThrombolysisOdds ratiomedicine.diseaseLower riskPulmonary embolismInternal medicineCohortmedicineDecompensationCardiology and Cardiovascular MedicinebusinessFibrinolytic agentEuropean Heart Journal
researchProduct

Identification of normotensive patients with pulmonary embolism who may benefit from thrombolysis.

2019

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentThrombolysismedicine.diseasePulmonary embolismFibrinolytic AgentsInternal medicinemedicineCardiologyHumansIdentification (biology)Thrombolytic TherapyCardiology and Cardiovascular MedicinebusinessPulmonary EmbolismInternational journal of cardiology
researchProduct

Early Mortality in Patients with Multiple Myeloma Treated with Novel Agents - Analysis from Polish Myeloma Study Group

2020

Background Although the introduction of novel agents improved the survival outcomes in patients with multiple myeloma (MM), some patients died within one year (early mortality, EM) following diagnosis. In this study, we evaluated the EM rate, and investigated the risk factors associated with EM in MM patients. Aims In this study we investigated risk factors associated with EM in MM patients initially treated with novel-agent containing regimen. Methods We conducted a multicenter (15 Polish sites) retrospective study a cohort of symptomatic MM pts diagnosed between October 2006 and November 2019 and living < 365 days (d) after diagnosis. All pts were dead at the time of the analysis. …

medicine.medical_specialtybusiness.operationbusiness.industryImmunologyRetrospective cohort studyCell BiologyHematologymedicine.diseaseOctapharmaBiochemistryThalidomideRegimenNovel agentsInternal medicineCohortMedicineIn patientbusinessMultiple myelomamedicine.drugBlood
researchProduct

Dopamine agonists in schizophrenia: a review.

1995

Although it is unlikely that the different types of course and severity of schizophrenia are caused by one neurochemical abnormality alone, indirect pharmacological evidence still suggests a relative excess of dopaminergic activity being implicated in the pathogenesis of most of the schizophrenic symptoms, e.g. positive symptomatology. Synthesis and release of dopamine as well as firing rates of dopaminergic neurons are controlled by stimulation of autoreceptors via a negative feedback regulation. Investigations on therapeutic effects of autoreceptor-nonselective dopamine agonists in schizophrenia have yielded inconsistent results. Dopamine autoreceptor agonists like pramipexole, roxindole,…

medicine.medical_specialtychemistry.chemical_compoundNeurochemicalPramipexoleRoxindoleDopamine receptor D3DopamineInternal medicineDopamine receptor D2medicineHumansPharmacology (medical)BenzothiazolesBiological PsychiatryAutoreceptorsPharmacologyPramipexoleDopaminergicAzepinesTalipexolePsychiatry and Mental healthThiazolesEndocrinologyNeurologychemistryDopamine AgonistsSchizophreniaNeurology (clinical)Psychologymedicine.drugAntipsychotic AgentsEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Glutathione, GlutathioneS-Transferase α and π, and Aldehyde Dehydrogenase Content in Relationship to Drug Resistance in Ovarian Cancer

1997

Glutathione, glutathione S-transferases alpha and pi, and aldehyde dehydrogenase are associated with resistance to carboplatin and/or cyclophosphamide in cell lines. Therefore, we examined whether the expression of these factors in ovarian cancer tissue specimens is associated with resistance of the patients to combination chemotherapy with cyclophosphamide/carboplatin. Ovarian cancer tissue specimens were taken intraoperatively from 139 patients and frozen in liquid nitrogen, and the contents of glutathione S-transferases alpha and pi, total glutathione, and aldehyde dehydrogenase activity were determined. No association between the levels of glutathione S-transferases alpha and pi or alde…

medicine.medical_specialtyendocrine system diseasesCyclophosphamidemedicine.medical_treatmentBlotting WesternAldehyde dehydrogenaseAntineoplastic AgentsOvaryCarboplatinchemistry.chemical_compoundInternal medicineHumansMedicineAntineoplastic Agents AlkylatingCyclophosphamideGlutathione TransferaseNeoplasm StagingOvarian NeoplasmsChemotherapybiologybusiness.industryObstetrics and GynecologyCombination chemotherapyGlutathioneAldehyde DehydrogenasePrognosismedicine.diseaseCombined Modality TherapyGlutathioneDrug Resistance Multiplefemale genital diseases and pregnancy complicationsCarboplatinmedicine.anatomical_structureEndocrinologyOncologychemistryDrug Resistance Neoplasmbiology.proteinCancer researchDrug Therapy CombinationFemaleCisplatinbusinessOvarian cancermedicine.drugGynecologic Oncology
researchProduct